Physician profile
Grant Williams
NPI 1316181241
$77,872.21
in general payments reported to CMS, 2019-2025
66 companies · $12K in 2025
The $12K reported for 2025 was more than what 90% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,001 · 2021: $1,269 · 2022: $390 · 2023: $4,684 · 2024: $57K · 2025: $12K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $60K · Food and Beverage: $8,145 · Travel and Lodging: $3,074 · Consulting Fee: $2,358 · Education: $14.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $59,622.50 |
| Food and Beverage | $8,145.06 |
| Travel and Lodging | $3,073.53 |
| Consulting Fee | $2,357.50 |
| Education | $14.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $63,667.31 | 2023-2025 | Fruzaqla, Ninlaro |
| Array Biopharma INC | $2,620.91 | 2019-2025 | Mektovi, Braftovi, Lorbrena |
| Astrazeneca Pharmaceuticals Lp | $1,905.35 | 2021-2025 | Imfinzi, Lynparza, Calquence |
| Bayer Healthcare Pharmaceuticals INC. | $1,648.58 | 2022-2025 | |
| E.R. Squibb & Sons, L.L.C. | $1,169.62 | 2021-2025 | Opdivo, Opdualag, Augtyro |
| Novartis Pharmaceuticals Corporation | $626.68 | 2023-2025 | |
| Ipsen Biopharmaceuticals, INC | $462.57 | 2022-2025 | Onivyde, Somatuline Depot |
| Eisai INC. | $433.09 | 2019-2025 | |
| Abbvie INC. | $378.02 | 2019-2025 | Venclexta |
| Merck Sharp & Dohme LLC | $339.90 | 2023-2025 | Keytruda, Lynparza, Welireg |
| Genentech USA, INC. | $305.47 | 2023-2025 | Tecentriq, Venclexta, Tecentriq Hybreza |
| Stemline Therapeutics INC. | $295.87 | 2023-2025 | Orserdu |
| Pfizer INC. | $284.65 | 2023-2025 | |
| Seagen INC. | $266.58 | 2023 | Tukysa, Tivdak, Padcev |
| Rigel Pharmaceuticals, INC. | $177.08 | 2022-2025 | Rezlidhia, Tavalisse, Gavreto |
Show all 65 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $167.08 | 2021-2024 | Verzenio, Jaypirca, Retevmo |
| Janssen Biotech, INC. | $160.46 | 2024-2025 | Darzalex, Talvey, Tecvayli |
| Regeneron Healthcare Solutions, INC. | $157.41 | 2023-2025 | Libtayo, Lynozyfic |
| Glaxosmithkline, LLC. | $141.57 | 2024-2025 | Ojjaara, Jemperli, Blenrep |
| Daiichi Sankyo INC. | $138.74 | 2024-2025 | Enhertu, Datroway, Injectafer |
| Incyte Corporation | $135.28 | 2023-2025 | Jakafi, Monjuvi, Zynyz |
| Advanced Accelerator Applications | $124.24 | 2019 | |
| Genzyme Corporation | $115.82 | 2023-2025 | |
| Celgene Corporation | $108.80 | 2023-2024 | Pomalyst, Reblozyl, Opdualag |
| Alexion Pharmaceuticals, INC. | $108.46 | 2023-2025 | Ultomiris |
| Blueprint Medicines Corporation | $105.24 | 2023-2025 | Ayvakit |
| Beone Medicines USA, INC. | $100.68 | 2025 | Brukinsa, Tevimbra |
| Servier Pharmaceuticals LLC | $91.98 | 2024-2025 | |
| Karyopharm Therapeutics INC. | $84.72 | 2023-2025 | Xpovio |
| Caris Mpi, INC. | $84.36 | 2025 | Mi Cancer Seek |
| Sumitomo Pharma America, INC. | $77.83 | 2023-2025 | Orgovyx |
| Exelixis INC. | $71.66 | 2023-2024 | Cabometyx |
| Pharmaessentia USA Corporation | $68.66 | 2023-2025 | Besremi |
| Gilead Sciences, INC. | $68.17 | 2025 | Trodelvy |
| Taiho Oncology, INC. | $66.48 | 2023-2025 | |
| Novocure INC. | $65.67 | 2025 | Optune Lua (Novottf-200t) |
| Mirati Therapeutics, INC. | $56.78 | 2023-2024 | Krazati |
| Kite Pharma, INC. | $56.49 | 2025 | Yescarta |
| Adaptive Biotechnologies Corporation | $55.51 | 2023-2024 | Clonoseq |
| Puma Biotechnology, INC. | $54.92 | 2024-2025 | |
| Springworks Therapeutics, INC. | $54.15 | 2025 | Ogsiveo |
| Genmab U.S., INC. | $53.47 | 2023-2025 | Epkinly |
| Deciphera Pharmaceuticals INC. | $51.81 | 2023-2025 | Qinlock, Romvimza |
| Myriad Genetic Laboratories, INC. | $48.95 | 2023-2024 | Bracanalysis Cdx, Myrisk |
| Pharmacyclics LLC, An Abbvie Company | $48.95 | 2023 | Imbruvica, Epkinly |
| Aveo Pharmaceuticals, INC. | $45.50 | 2023-2025 | Fotivda |
| Sobi, INC | $42.81 | 2024-2025 | |
| Geron Corporation | $41.82 | 2025 | Rytelo |
| Agios Pharmaceuticals, INC. | $41.43 | 2023-2025 | Pyrukynd |
| Emd Serono, INC. | $38.98 | 2024-2025 | |
| Beigene USA, INC. | $35.96 | 2024 | Brukinsa, Tevimbra |
| Sirtex Medical INC | $32.53 | 2019 | |
| Immunocore Limited | $29.53 | 2025 | Kimmtrak |
| Sun Pharmaceutical Industries INC. | $28.76 | 2023 | Odomzo, Yonsa |
| Tersera Therapeutics LLC | $27.62 | 2025 | Zoladex |
| Astellas Pharma US INC | $24.57 | 2025 | Xtandi |
| Jazz Pharmaceuticals INC. | $24.29 | 2024 | |
| Pharmacosmos Therapeutics INC. | $24.26 | 2025 | Monoferric |
| Boehringer Ingelheim Pharmaceuticals, INC. | $22.98 | 2024 | Gilotrif |
| Fennec Pharmaceuticals, INC. | $22.60 | 2025 | Fyarro |
| Coherus Oncology, INC. | $19.59 | 2025 | Loqtorzi |
| Janssen Pharmaceuticals, INC | $17.01 | 2024 | Xarelto |
| Progenics Pharmaceuticals, INC. | $16.77 | 2025 | |
| Acrotech Biopharma INC. | $15.97 | 2025 | Beleodaq |
| Morphosys, US INC. | $13.21 | 2021 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Grant Williams listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.